Insulin resistance impairs nigrostriatal dopamine function

Experimental Neurology

Volumn 231, Issue 1, 2011, Pages 171-180

  Morris, J K ^a   Bomhoff, G L ^a   Gorres, B K ^a   Davis, V A ^c   Kim, J ^b   Lee, P P ^a,b   Brooks, W M ^a,b   Gerhardt, G A ^c   Geiger, P C ^a,b   Stanford, J A ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Diabetes; Glucose; High fat diet; Insulin; Iron; Parkinson's disease

Indexed keywords

DOPAMINE; POTASSIUM; PROTEIN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DOPAMINE RELEASE; ELECTROCHEMISTRY; EVOKED RESPONSE; FAT INTAKE; HEMOSIDEROSIS; IN VIVO STUDY; INSULIN RESISTANCE; IRON METABOLISM; MALE; NIGRONEOSTRIATAL SYSTEM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT;

ANIMALS; CORPUS STRIATUM; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIETARY FATS; DISEASE MODELS, ANIMAL; DOPAMINE; INSULIN RESISTANCE; IRON; IRON METABOLISM DISORDERS; MALE; NEURAL PATHWAYS; PARKINSON DISEASE; RATS; RATS, INBRED F344; SUBSTANTIA NIGRA;

EID: 79961030579     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.06.005     Document Type: Article

References (75)

1. Abbott R.D., Ross G.W., White L.R., Nelson J.S., Masaki K.H., Tanner C.M., Curb J.D., Blanchette P.L., Popper J.S., Petrovitch H. Midlife adiposity and the future risk of Parkinson's disease. Neurology 2002, 59:1051-1057.
2. Alessi D.R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., Hemmings B.A. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996, 15:6541-6551.
3. Anderson C., Checkoway H., Franklin G.M., Beresford S., Smith-Weller T., Swanson P.D. Dietary factors in Parkinson's disease: the role of food groups and specific foods. Mov. Disord. 1999, 14:21-27.
4. Anderson G.J., Vulpe C.D. Mammalian iron transport. Cell Mol. Life Sci. 2009, 66:3241-3261.
5. Andrews Z.B., Erion D., Beiler R., Liu Z.W., Abizaid A., Zigman J., Elsworth J.D., Savitt J.M., DiMarchi R., Tschoep M., Roth R.H., Gao X.B., Horvath T.L. Ghrelin promotes and protects nigrostriatal dopamine function via a UCP2-dependent mitochondrial mechanism. J. Neurosci. 2009, 29:14057-14065.
6. Arvanitakis Z., Wilson R.S., Bienias J.L., Bennett D.A. Diabetes and parkinsonian signs in older persons. Alzheimer Dis. Assoc. Disord. 2007, 21:144-149.
7. Aydemir F., Jenkitkasemwong S., Gulec S., Knutson M.D. Iron loading increases ferroportin heterogeneous nuclear RNA and mRNA levels in murine J774 macrophages. J. Nutr. 2009, 139:434-438.
8. Banks W.A. The source of cerebral insulin. Eur. J. Pharmacol. 2004, 490:5-12.
9. Baura G.D., Foster D.M., Porte D., Kahn S.E., Bergman R.N., Cobelli C., Schwartz M.W. Saturable transport of insulin from plasma into the central nervous system of dogs in vivo. A mechanism for regulated insulin delivery to the brain. J. Clin. Invest. 1993, 92:1824-1830.
10. Beal M.F. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann. N. Y. Acad. Sci. 2003, 991:120-131.
11. Benedict C., Frey W.H., Schioth H.B., Schultes B., Born J., Hallschmid M. Intranasal insulin as a therapeutic option in the treatment of cognitive impairments. Exp. Gerontol. 2011, 46:112-115.
12. Benomar Y., Roy A.F., Aubourg A., Djiane J., Taouis M. Cross down-regulation of leptin and insulin receptor expression and signalling in a human neuronal cell line. Biochem. J. 2005, 388:929-939.
13. Bharath S., Hsu M., Kaur D., Rajagopalan S., Andersen J.K. Glutathione, iron and Parkinson's disease. Biochem. Pharmacol. 2002, 64:1037-1048.
14. Brass S.D., Chen N.K., Mulkern R.V., Bakshi R. Magnetic resonance imaging of iron deposition in neurological disorders. Top. Magn. Reson. Imaging 2006, 17:31-40.
15. Cass W.A., Zahniser N.R., Flach K.A., Gerhardt G.A. Clearance of exogenous dopamine in rat dorsal striatum and nucleus accumbens: role of metabolism and effects of locally applied uptake inhibitors. J. Neurochem. 1993, 61:2269-2278.
16. Choi J.Y., Jang E.H., Park C.S., Kang J.H. Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity. Free Radic. Biol. Med. 2005, 38:806-816.
17. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch. Neurol. 2009, 66:300-305.
18. Davis J.F., Tracy A.L., Schurdak J.D., Tschop M.H., Lipton J.W., Clegg D.J., Benoit S.C. Exposure to elevated levels of dietary fat attenuates psychostimulant reward and mesolimbic dopamine turnover in the rat. Behav. Neurosci. 2008, 122:1257-1263.
19. Davis R.J., Corvera S., Czech M.P. Insulin stimulates cellular iron uptake and causes the redistribution of intracellular transferrin receptors to the plasma membrane. J. Biol. Chem. 1986, 261:8708-8711.
20. Delhanty P.J., van der Eerden B.C., van der Velde M., Gauna C., Pols H.A., Jahr H., Chiba H., van der Lely A.J., van Leeuwen J.P. Ghrelin and unacylated ghrelin stimulate human osteoblast growth via mitogen-activated protein kinase (MAPK)/phosphoinositide 3-kinase (PI3K) pathways in the absence of GHS-R1a. J. Endocrinol. 2006, 188:37-47.
21. Eberhardt M.S., Engelgau M., Cadwell B. Prevalence of overweight and obesity among adults with diagnosed diabetes-United States, 1988-1994 and 1999-2002. MMWR Morb. Mortal. Wkly Rep. 2004, 53:1066-1068.
22. Fachinetto R., Burger M.E., Wagner C., Wondracek D.C., Brito V.B., Nogueira C.W., Ferreira J., Rocha J.B. High fat diet increases the incidence of orofacial dyskinesia and oxidative stress in specific brain regions of rats. Pharmacol. Biochem. Behav. 2005, 81:585-592.
23. Fernandez-Real J.M., Lopez-Bermejo A., Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 2002, 51:2348-2354.
24. Geiger B.M., Haburcak M., Avena N.M., Moyer M.C., Hoebel B.G., Pothos E.N. Deficits of mesolimbic dopamine neurotransmission in rat dietary obesity. Neuroscience 2009, 159:1193-1199.
25. Graham J.M., Paley M.N., Grunewald R.A., Hoggard N., Griffiths P.D. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 2000, 123(Pt 12):2423-2431.
26. Gupte A.A., Bomhoff G.L., Morris J.K., Gorres B.K., Geiger P.C. Lipoic acid increases heat shock protein expression and inhibits stress kinase activation to improve insulin signaling in skeletal muscle from high-fat-fed rats. J. Appl. Physiol. 2009, 106:1425-1434.
27. Hatcher J.M., Richardson J.R., Guillot T.S., McCormack A.L., Di Monte D.A., Jones D.P., Pennell K.D., Miller G.W. Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system. Exp. Neurol. 2007, 204:619-630.
28. Hebert M.A., Gerhardt G.A. Normal and drug-induced locomotor behavior in aging: comparison to evoked DA release and tissue content in Fischer 344 rats. Brain Res. 1998, 797:42-54.
29. Hindle J.V. Ageing, neurodegeneration and Parkinson's disease. Age Ageing 2010, 39:156-161.
30. Hoffman A.F., Gerhardt G.A. In vivo electrochemical studies of dopamine clearance in the rat substantia nigra: effects of locally applied uptake inhibitors and unilateral 6-hydroxydopamine lesions. J. Neurochem. 1998, 70:179-189.
31. Hu G., Jousilahti P., Bidel S., Antikainen R., Tuomilehto J. Type 2 diabetes and the risk of Parkinson's disease. Diab. Care 2007, 30:842-847.
32. Hu G., Jousilahti P., Nissinen A., Antikainen R., Kivipelto M., Tuomilehto J. Body mass index and the risk of Parkinson disease. Neurology 2006, 67:1955-1959.
33. Irvine E.E., Drinkwater L., Radwanska K., Al-Qassab H., Smith M.A., O'Brien M., Kielar C., Choudhury A.I., Krauss S., Cooper J.D., Withers D.J., Giese K.P. Insulin receptor substrate 2 is a negative regulator of memory formation. Learn. Mem. 2011, 18:375-383.
34. Johnson C.C., Gorell J.M., Rybicki B.A., Sanders K., Peterson E.L. Adult nutrient intake as a risk factor for Parkinson's disease. Int. J. Epidemiol. 1999, 28:1102-1109.
35. Kaur D., Lee D., Ragapolan S., Andersen J.K. Glutathione depletion in immortalized midbrain-derived dopaminergic neurons results in increases in the labile iron pool: implications for Parkinson's disease. Free Radic. Biol. Med. 2009, 46:593-598.
36. Ko K.W., Avramoglu R.K., McLeod R.S., Vukmirica J., Yao Z. The insulin-stimulated cell surface presentation of low density lipoprotein receptor-related protein in 3T3-L1 adipocytes is sensitive to phosphatidylinositide 3-kinase inhibition. Biochemistry 2001, 40:752-759.
37. Logroscino G., Marder K., Cote L., Tang M.X., Shea S., Mayeux R. Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. Ann. Neurol. 1996, 39:89-94.
38. Macdonald P.A., Monchi O. Differential effects of dopaminergic therapies on dorsal and ventral striatum in Parkinson's disease: implications for cognitive function. Parkinsons Dis. 2011, 2011:572743.
39. Maffei M., Halaas J., Ravussin E., Pratley R.E., Lee G.H., Zhang Y., Fei H., Kim S., Lallone R., Ranganathan S., et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat. Med. 1995, 1:1155-1161.
40. Mastroberardino P.G., Hoffman E.K., Horowitz M.P., Betarbet R., Taylor G., Cheng D., Na H.M., Gutekunst C.A., Gearing M., Trojanowski J.Q., Anderson M., Chu C.T., Peng J., Greenamyre J.T. A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiol. Dis. 2009, 34:417-431.
41. Matsuzawa-Nagata N., Takamura T., Ando H., Nakamura S., Kurita S., Misu H., Ota T., Yokoyama M., Honda M., Miyamoto K.I., Kaneko S. Increased oxidative stress precedes the onset of high-fat diet-induced insulin resistance and obesity. Metabolism 2008, 57:1071-1077.
42. Moon M., Kim H.G., Hwang L., Seo J.H., Kim S., Hwang S., Kim S., Lee D., Chung H., Oh M.S., Lee K.T., Park S. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation. Neurotox. Res. 2009, 15:332-347.
43. Moroo I., Yamada T., Makino H., Tooyama I., McGeer P.L., McGeer E.G., Hirayama K. Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease. Acta Neuropathol. 1994, 87:343-348.
44. Morris J.K., Bomhoff G.L., Stanford J.A., Geiger P.C. Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high fat diet. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010, 299(4):R1082-R1090.
45. Morris J.K., Zhang H., Gupte A.A., Bomhoff G.L., Stanford J.A., Geiger P.C. Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease. Brain Res. 2008, 1240:185-195.
46. Morrison C.D., Pistell P.J., Ingram D.K., Johnson W.D., Liu Y., Fernandez-Kim S.O., White C.L., Purpera M.N., Uranga R.M., Bruce-Keller A.J., Keller J.N. High fat diet increases hippocampal oxidative stress and cognitive impairment in aged mice: implications for decreased Nrf2 signaling. J. Neurochem. 2010, 114:1581-1589.
47. Nemeth E., Ganz T. Regulation of iron metabolism by hepcidin. Annu. Rev. Nutr. 2006, 26:323-342.
48. Papapetropoulos S., Ellul J., Argyriou A.A., Talelli P., Chroni E., Papapetropoulos T. The effect of vascular disease on late onset Parkinson's disease. Eur. J. Neurol. 2004, 11:231-235.
49. Priyadarshi A., Khuder S.A., Schaub E.A., Priyadarshi S.S. Environmental risk factors and Parkinson's disease: a metaanalysis. Environ. Res. 2001, 86:122-127.
50. Priyadarshi A., Khuder S.A., Schaub E.A., Shrivastava S. A meta-analysis of Parkinson's disease and exposure to pesticides. Neurotoxicology 2000, 21:435-440.
51. Qiu W.Q., Ye Z., Kholodenko D., Seubert P., Selkoe D.J. Degradation of amyloid beta-protein by a metalloprotease secreted by microglia and other neural and non-neural cells. J. Biol. Chem. 1997, 272:6641-6646.
52. Rajpathak S.N., Crandall J.P., Wylie-Rosett J., Kabat G.C., Rohan T.E., Hu F.B. The role of iron in type 2 diabetes in humans. Biochim. Biophys. Acta 2009, 1790:671-681.
53. Rhodes S.L., Ritz B. Genetics of iron regulation and the possible role of iron in Parkinson's disease. Neurobiol. Dis. 2008, 32:183-195.
54. Richardson D.R., Lane D.J., Becker E.M., Huang M.L., Whitnall M., Rahmanto Y.S., Sheftel A.D., Ponka P. Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:10775-10782.
55. Salazar J., Mena N., Hunot S., Prigent A., Alvarez-Fischer D., Arredondo M., Duyckaerts C., Sazdovitch V., Zhao L., Garrick L.M., Nunez M.T., Garrick M.D., Raisman-Vozari R., Hirsch E.C. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:18578-18583.
56. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989, 1:1269.
57. Schenck J.F., Zimmerman E.A. High-field magnetic resonance imaging of brain iron: birth of a biomarker?. NMR Biomed. 2004, 17:433-445.
58. Schernhammer E., Hansen J., Rugbjerg K., Wermuth L., Ritz B. Diabetes and the risk of developing Parkinson's disease in Denmark. Diab. Care 2011, 34:1102-1108.
59. Seo A.Y., Xu J., Servais S., Hofer T., Marzetti E., Wohlgemuth S.E., Knutson M.D., Chung H.Y., Leeuwenburgh C. Mitochondrial iron accumulation with age and functional consequences. Aging Cell 2008, 7:706-716.
60. South T., Huang X.F. High-fat diet exposure increases dopamine D2 receptor and decreases dopamine transporter receptor binding density in the nucleus accumbens and caudate putamen of mice. Neurochem. Res. 2008, 33:598-605.
61. Stanford J.A., Currier T.D., Purdom M.S., Gerhardt G.A. Nomifensine reveals age-related changes in K(+)-evoked striatal DA overflow in F344 rats. Neurobiol. Aging. 2001, 22:495-502.
62. Stanford J.A., Gerhardt G.A. Aged F344 rats exhibit altered electrophysiological activity in locomotor-unrelated but not locomotor-related striatal neurons. Neurobiol. Aging 2004, 25:509-515.
63. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci. 2007, 30:244-250.
64. Swaminathan S., Fonseca V.A., Alam M.G., Shah S.V. The role of iron in diabetes and its complications. Diab. Care 2007, 30:1926-1933.
65. Taguchi A., Wartschow L.M., White M.F. Brain IRS2 signaling coordinates life span and nutrient homeostasis. Science 2007, 317:369-372.
66. Tanner L.I., Lienhard G.E. Localization of transferrin receptors and insulin-like growth factor II receptors in vesicles from 3T3-L1 adipocytes that contain intracellular glucose transporters. J. Cell Biol. 1989, 108:1537-1545.
67. van der Heide L.P., Ramakers G.M., Smidt M.P. Insulin signaling in the central nervous system: learning to survive. Prog. Neurobiol. 2006, 79:205-221.
68. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling. Diab. Care 2004, 27:1487-1495.
69. Wallis L.I., Paley M.N., Graham J.M., Grunewald R.A., Wignall E.L., Joy H.M., Griffiths P.D. MRI assessment of basal ganglia iron deposition in Parkinson's disease. J. Magn. Reson. Imaging 2008, 28:1061-1067.
70. Wang W., Knovich M.A., Coffman L.G., Torti F.M., Torti S.V. Serum ferritin: past, present and future. Biochim. Biophys. Acta 2010, 1800:760-769.
71. West A.R., Galloway M.P. Nitric oxide and potassium chloride-facilitated striatal dopamine efflux in vivo: role of calcium-dependent release mechanisms. Neurochem. Int. 1998, 33:493-501.
72. Xu Q., Park Y., Huang X., Hollenbeck A., Blair A., Schatzkin A., Chen H. Diabetes and risk of Parkinson's disease. Diab. Care 2011, 34:910-915.
73. Yang F., Wang X., Haile D.J., Piantadosi C.A., Ghio A.J. Iron increases expression of iron-export protein MTP1 in lung cells. Am. J. Physiol. Lung Cell Mol. Physiol. 2002, 283:L932-L939.
74. York D.A., Teng L., Park-York M. Effects of dietary fat and enterostatin on dopamine and 5-hydroxytrytamine release from rat striatal slices. Brain Res. 2010, 1349:48-55.
75. Zhang X., Dong F., Ren J., Driscoll M.J., Culver B. High dietary fat induces NADPH oxidase-associated oxidative stress and inflammation in rat cerebral cortex. Exp. Neurol. 2005, 191:318-325.